Last reviewed 2026-04-23 · How we verify

GP2015

GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells.

GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells. Used for Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy.

At a glance

Mechanism of action

GP2015 is designed as a biosimilar to pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF). It binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation into mature neutrophils. This mechanism helps reduce the incidence of chemotherapy-induced neutropenia and its complications in cancer patients receiving myelosuppressive chemotherapy.

Approved indications

• Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy

Common side effects

• Bone pain
• Injection site reactions
• Headache
• Fatigue
• Nausea

Key clinical trials

• Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (PHASE3)
• Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GP2015 CI brief — competitive landscape report
• GP2015 updates RSS · CI watch RSS
• Sandoz portfolio CI